What the FDA labels say about taking them together
Haloperidol and tetrabenazine
Tetrabenazine's FDA label of November 29, 2019 names haloperidol in its drug interactions section; the haloperidol labels PlainMeds reads (2) do not name tetrabenazine.
Check it at the source: the haloperidol FDA label on DailyMed (effective April 23, 2026, PD-Rx Pharmaceuticals, Inc.); the tetrabenazine FDA label on DailyMed (effective November 29, 2019, Oceanside Pharmaceuticals).
What does the haloperidol label say about tetrabenazine?
Haloperidol's label (effective April 23, 2026) and its 1 other brand-application label do not name tetrabenazine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Haloperidol), PD-Rx Pharmaceuticals, Inc., effective April 23, 2026 (SPL set 533b0b4c-cbd6-4ec0-a333-8b04b5b43a1d), via openFDA; the full label on DailyMed
What does the tetrabenazine label say about haloperidol?
Tetrabenazine label, drug interactionsTetrabenazine tablets cause a small prolongation of QTc (about 8 msec), concomitant use with other drugs that are known to cause QTc prolongation should be avoided, these including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval.
Tetrabenazine label, warnings and precautionsThe use of tetrabenazine tablets should be avoided in combination with other drugs that are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval [see Drug Interactions ( 7.5 )].
Source: FDA drug label (tetrabenazine), NDA021894 (Bausch), as published by Oceanside Pharmaceuticals, effective November 29, 2019 (SPL set 5867189c-17bd-4e70-a079-c4730f9950d1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Haloperidol | Tetrabenazine | |
|---|---|---|
| Labeled for | Schizophrenia | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $15.60 per mL 100 mg/mL vial | $0.702 per tablet 12.5 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once